News Conference News CRT 2025 AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years L.A. McKeown March 10, 2025
News Conference News BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years Caitlin E. Cox March 02, 2022
News Conference News CRT 2019 Rivaroxaban in Addition to DAPT Lowers Death, MI, Stroke in ACS, Heart Failure Patients: Meta-analysis Yael L. Maxwell March 03, 2019
News Conference News CRT 2017 Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate Michael O'Riordan February 21, 2017